A treatment trial of the monoclonal anti-amyloid antibody solanezumab showed slight benefits in people with dementia due to mild Alzheimer disease. Drug effects on several neuropsychological testing outcomes were statistically significant, but the effect sizes were unlikely to manifest as meaningful functional benefits. Here, we discuss the implications and possible molecular underpinnings.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siemers, E. R. et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. http://dx.doi.org/10.1016/j.jalz.2015.06.1893.
Liu, E. et al. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85, 692–700 (2015).
Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938 (2015).
Jack, C. R. Jr et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81, 1732–1740 (2013).
Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448–6453 (1998).
Schöll, M. et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 79, 229–236 (2012).
Lim, Y. Y. et al. Effect of amyloid on memory and decline from preclinical to clinical Alzheimer's disease. Brain 137, 221–231 (2014).
Ramanan, V. K. et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain http://dx.doi.org/10.1093/brain/awv231.
Lambert, J.-C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45, 1452–1458 (2013).
Sperling, R. A. et al. The A4 study: stopping AD before symptoms begin? Sci. Transl. Med. 6, 228fs13 (2014).
The authors acknowledge NIH grants P50 AG005138 (to M.S.), and U01 AG046170, R34 AG049649, R01 NS075685, R21 AT005510, RF1 AG042965, VA MERIT Review Grant I01 RX000684, the Cure Alzheimer's Fund, and gifts from the Louis B. Mayer Foundation, the Sarah and Gideon Gartner Trust, the Rudin Foundation, and the Werber Family Foundation (to S.G.).
Within the past 5 years, S.G. has provided consultation to the Janssen Pfizer Immunotherapy Alliance and has held grants from Baxter, Amicus and Constellation/Polyphenolics. M.S. has provided consultation to Janssen Pharmaceuticals, Eli Lilly, Eisai, Medivation, Sanofi Aventis, Biogen and Takeda. She has also consulted for Merck and Nutricia without any compensation.
About this article
Cite this article
Gandy, S., Sano, M. Solanezumab—prospects for meaningful interventions in AD?. Nat Rev Neurol 11, 669–670 (2015). https://doi.org/10.1038/nrneurol.2015.218
Translational Neurodegeneration (2018)